Background: Congenital cytomegalovirus (CMV) infection occurs when a fetus acquires the virus from a mother infected with CMV during pregnancy, transmitting it through the placenta. Currently, both ganciclovir (GCV) and its prodrug, valganciclovir (VGCV), are approved for the treatment and prophylaxis of CMV infections in immunocompromised patients and other CMV-associated diseases. However, no study has […]
